Literature DB >> 24570201

Optimal surgical management for esophagogastric junction carcinoma.

Tatsuo Matsuda1, Hiroya Takeuchi, Shinichi Tsuwano, Rieko Nakamura, Tsunehiro Takahashi, Norihito Wada, Hirofumi Kawakubo, Yoshiro Saikawa, Tai Omori, Yuko Kitagawa.   

Abstract

OBJECTIVES: Esophagogastric junction carcinoma incidence is increasing worldwide. However, surgical strategies for this cancer remain controversial. This study aimed to clarify the optimal surgical strategy for esophagogastric junction carcinoma.
METHODS: We retrospectively reviewed a database of 68 consecutive patients with esophagogastric junction carcinoma [Japanese classification of gastric carcinoma (Nishi's definition): adenocarcinoma, N=53; squamous cell carcinoma, N=15] who underwent curative surgical resection at Keio University Hospital between January 2000 and September 2008.
RESULTS: In both adenocarcinoma and squamous cell carcinoma, most lymph node metastases were located in the lesser curvature area. Mediastinal lymph node metastasis was observed in 4 patients (7.5%) with adenocarcinoma and 7 patients (46.7%) with squamous cell carcinoma. No patient presented with lymph node metastases in the pyloric region. The therapeutic value of extended lymph node dissection was 0, except for lymph node station numbers 1, 2, 3, 4sa, 7, and 110. Extended lymph node dissection in the lesser curvature area showed a high therapeutic value. The para-aortic lymph node was the most frequent nodal recurrence site. All patients with tumor centers located below the esophagogastric junction (N=37) did not develop mediastinal lymph node metastasis or recurrence.
CONCLUSIONS: Proximal gastrectomy through a transhiatal approach may be the optimal surgical strategy for esophagogastric carcinoma. Mediastinal lymph node dissection through a thoracic approach seems unnecessary, particularly when the tumor center is located below the esophagogastric junction. To confirm the necessity of para-aortic nodal dissection, further studies are required.

Entities:  

Mesh:

Year:  2014        PMID: 24570201     DOI: 10.1007/s11748-014-0381-2

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  20 in total

1.  Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites.

Authors:  S Hansen; J N Wiig; K E Giercksky; S Tretli
Journal:  Int J Cancer       Date:  1997-05-02       Impact factor: 7.396

Review 2.  Surgical treatment for gastric cancer: the Japanese approach.

Authors:  K Maruyama; M Sasako; T Kinoshita; T Sano; H Katai
Journal:  Semin Oncol       Date:  1996-06       Impact factor: 4.929

3.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

4.  The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction.

Authors:  S M Dresner; P J Lamb; M K Bennett; N Hayes; S M Griffin
Journal:  Surgery       Date:  2001-01       Impact factor: 3.982

5.  New method to evaluate the therapeutic value of lymph node dissection for gastric cancer.

Authors:  M Sasako; P McCulloch; T Kinoshita; K Maruyama
Journal:  Br J Surg       Date:  1995-03       Impact factor: 6.939

6.  Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Hitoshi Katai; Shinji Morita; Makoto Saka; Hirokazu Taniguchi; Takeo Fukagawa
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

7.  Cardia carcinoma considered as a distinct clinical entity.

Authors:  B Husemann
Journal:  Br J Surg       Date:  1989-02       Impact factor: 6.939

8.  Lymph node metastasis in patients with adenocarcinoma of gastric cardia.

Authors:  L S Wang; C W Wu; M J Hsieh; H J Fahn; M H Huang; K Y Chien
Journal:  Cancer       Date:  1993-03-15       Impact factor: 6.860

9.  Surgical outcomes for cancer at the gastroesophageal junction.

Authors:  Sohei Matsumoto; Tomoyoshi Takayama; Kohei Wakatsuki; Koji Enomoto; Tetsuya Tanaka; Kazuhiro Migita; Masahiro Ito; Yoshiyuki Nakajima
Journal:  Am Surg       Date:  2012-11       Impact factor: 0.688

10.  Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study.

Authors:  Hiroaki Ito; Haruhiro Inoue; Noriko Odaka; Hitoshi Satodate; Michitaka Suzuki; Shumpei Mukai; Yusuke Takehara; Hiroyuki Kida; Shin-Ei Kudo
Journal:  J Exp Clin Cancer Res       Date:  2013-01-07
View more
  5 in total

1.  Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Jian-Kun Hu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

2.  Distribution of lymph node metastases in locally advanced adenocarcinomas of the esophagogastric junction (cT2-4): comparison between Siewert type I and selected Siewert type II tumors.

Authors:  Akio Sakaki; Jun Kanamori; Koshiro Ishiyama; Daisuke Kurita; Junya Oguma; Hiroyuki Daiko
Journal:  Langenbecks Arch Surg       Date:  2020-06-08       Impact factor: 3.445

3.  Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.

Authors:  Haijun Li; E Bai; Yong Zhang; Zhuoqi Jia; Shicai He; Junke Fu
Journal:  J Immunol Res       Date:  2017-01-11       Impact factor: 4.818

4.  High-risk group of upper and middle mediastinal lymph node metastasis in patients with esophagogastric junction carcinoma.

Authors:  Masahiro Yura; Hiroya Takeuchi; Kazumasa Fukuda; Rieko Nakamura; Koichi Suda; Norihito Wada; Hirofumi Kawakubo; Yuko Kitagawa
Journal:  Ann Gastroenterol Surg       Date:  2018-10-13

5.  Optimal Extent of Transhiatal Gastrectomy and Lymphadenectomy for the Stomach-Predominant Adenocarcinoma of Esophagogastric Junction: Retrospective Single-Institution Study in China.

Authors:  Baoyu Zhao; Zhenzhan Zhang; Debin Mo; Yiming Lu; Yanfeng Hu; Jiang Yu; Hao Liu; Guoxin Li
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.